Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2

YONGSHENG XIE1*, BO LI2*, WENXUAN BU1*, LU GAO1, YONG ZHANG2, XIUCAI LAN1, JUN HOU1, ZHIJIAN XU2, SHUAIKANG CHANG1, DANDAN YU1, BINGQIAN XIE1, YINGCONG WANG1, HOUCAI WANG1, YIWEN ZHANG1, XIAOSONG WU1, WEILIANG ZHU2 and JUMEI SHI1,3

1Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072; 2CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203; 3Department of Hematology, Tongji University Cancer Center, Tongji University, Shanghai 200092, P.R. China

Received January 24, 2018; Accepted May 16, 2018

DOI: 10.3892/ijo.2018.4438

Abstract. Mantle cell lymphoma (MCL) is a distinct and highly aggressive subtype of B-cell non-Hodgkin lymphoma. Dihydrocelastrol (DHCE) is a dihydro-analog of celastrol, which is isolated from the traditional Chinese medicinal plant Tripterygium wilfordii. The present study aimed to investigate the effects of DHCE treatment on MCL cells, and to determine the mechanism underlying its potent antitumor activity in vitro and in vivo using the Cell Counting kit-8 assay, clonogenic assay, apoptosis assay, cell cycle analysis, immunofluorescence staining, western blotting and tumor xenograft models. The results demonstrated that DHCE treatment exerted minimal cytotoxic effects on normal cells, but markedly suppressed MCL cell proliferation by inducing G0/G1 phase cell cycle arrest, and inhibited MCL cell viability by stimulating apoptosis via extrinsic and intrinsic pathways. In addition, the results revealed that DHCE suppressed cell growth and proliferation by inhibiting mammalian target of rapamycin complex (mTORC)1-mediated phosphorylation of ribosomal protein S6 kinase and eukaryotic initiation factor 4E binding protein. Simultaneously, DHCE induced apoptosis and inhibited cell survival by suppressing mTORC2-mediated phosphorylation of protein kinase B and nuclear factor-κB activity. In addition to in vitro findings, DHCE treatment reduced the MCL tumor burden in a xenograft mouse model, without indications of toxicity. Furthermore, combined treatment with DHCE and bortezomib, a proteasome inhibitor, induced a synergistic cytotoxic effect on MCL cells. These findings indicated that DHCE may have the potential to serve as a novel therapeutic agent for the treatment of MCL through dually inhibiting mTORC1 and mTORC2.

Introduction

Mantle cell lymphoma (MCL) is a highly aggressive subtype of B-cell lymphoma, which accounts for 6-8% of all non-Hodgkin lymphoma diagnoses (1). The malignant cells are present in the mantle zone of the lymph node (2) and are characterized by the molecular hallmark of translocation t(11;14)(q13;q32), which is associated with cyclin D1 overexpression (3,4). More than 80% of patients with MCL are diagnosed at stage III or IV of the disease, which is characterized by lymphadenopathy, hepatosplenomegaly and bone marrow involvement (5). Over the last decade, high-dose cytarabine and autologous stem cell transplantation have been used to treat younger patients, whereas rituximab and bendamustine are used to treat older patients. Furthermore, the proteasome inhibitor bortezomib, the immunomodulator lenalidomide, and the Bruton’s tyrosine kinase inhibitor ibrutinib have been approved for use in novel therapeutic regimens (4). Although these therapeutic regimens initially exhibit a high rate of complete response, the majority of patients receiving these treatments experience short remission duration with a continuous relapse pattern, leading to incurable MCL with a median survival period of 4-5 years (6). Therefore, there is an urgent need to explore novel molecular targeting agents for the treatment of MCL.

Mammalian target of rapamycin (mTOR) is a highly conserved 289 kDa serine/threonine kinase (7), which is involved in various signaling pathways, including Ras, phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt), hypoxia-inducible factor-1 and nuclear factor (NF)-κB. mTOR serves a critical role in the regulation of cell differentiation,
proliferation and survival (8), and is associated with tumori-
genesis, angiogenesis, tumor growth and metastasis (9-11). In
addition, mTOR is aberrantly activated in various malignant-
cies and is an indicator of more aggressive diseases, as well
as poorer disease prognosis (10-13). mTOR serves as the
catalytic subunit of two distinct protein complexes, known as
mTOR complex (mTORC)1 and mTORC2. mTORC1 contains
mTOR, Raptor and mTOR-associated protein, LST8 homolog
(mLST8), whereas mTORC2 is formed by mTOR, Rictor and
mLST8 (14). mTORC1 phosphorylates ribosomal protein S6
kinase (p70S6K) and eukaryotic initiation factor 4E binding
protein (4E-BP1), which results in protein, nucleotide and
lipid synthesis for cell growth and proliferation. mTORC2
autophosphorylates mTOR on Ser2481, and also phosphory-
lates Akt on Ser473 to control survival and apoptosis (15,16).
Numerous hematological malignancies exhibit elevated or
aberrant mTOR activation, and mTORC1 and mTORC2 are
activated in primary MCL specimens (17). Therefore,
numerous clinical trials aimed at evaluating the potential of
single agent mTOR-targeted therapies have been launched.
Weekly intravenous injection of the mTOR inhibitor temsi-
rolimus has been reported to result in an overall response
rate of 38 and 41% in two studies of patients with relapsed
MCL (18,19). Several other clinical trials have indicated that
mTOR inhibition can produce antitumor responses in relapsed
lymphoma. However, the use of an mTOR targeting agent
as a novel therapeutic regimen requires further exploration,
particularly for lymphoid malignancies such as MCL (12-14).

Celastrol is a triterpene purified from Tripterygium
wilfordii Hook, which possesses antioxidative, anti-apoptotic,
ant-inflammatory, anticancerogenic and anti-obesity proper-
ties (20,21). In previous studies, celastrol has been reported to
exert antitumor effects on leukemia (22), breast cancer (23),
and head and neck cancer (24), as well as other types of tumor.
However, the precise mechanism of action of celastrol in
lymphoma, particularly in MCL, has not been fully elucidated.

The present study synthesized dihydrocelastrol (DHCE)
as a dihydro-analog of celastrol. DHCE exerted potent anti-
tumor activity in MCL cells, in vitro and in vivo, with minimal
cytotoxic effects on normal cells. Furthermore, the molecular
mechanisms of DHCE action were investigated, and the results
revealed that DHCE was an effective inhibitor of mTORC1
and mTORC2. DHCE suppressed growth and proliferation by
inhibiting mTORC1-mediated phosphorylation of p70S6K
and 4E-BP1. Simultaneously, DHCE induced apoptosis and
inhibited cell survival by suppressing mTORC2-mediated
phosphorylation of Akt and NF-κB activity. Taken together,
these findings suggested that DHCE may have the potential to
serve as a novel therapeutic agent for the treatment of MCL.

Materials and methods

Cells and cell culture. The human MCL cell lines Jeko-1
and Granta519 were purchased from American Type Culture
Collection (Manassas, VA, USA). The human MCL cell lines
Z138, Mino and Rec-1 were provided by Dr Xue Han of Tianjin
Medical University Cancer Hospital (Tianjin, China). Human
peripheral blood mononuclear cells (PBMCs) were acquired
from three healthy normal donors (2 males, 1 female; age, 24,
24 and 28 years, respectively) using Ficoll-Hypaque density
gradient centrifugation at 568 x g for 30 min at room tempera-
ture. Informed consent was obtained from each healthy donor.
The present study was approved by the institutional review
board of Shanghai Tenth People's Hospital (Shanghai, China).
The cells were cultured in RPMI-1640 medium (Gibco;
Thermo Fisher Scientific, Inc., Waltham, MA, USA) supple-
mented with 10% fetal bovine serum (FBS; Gibco; Thermo
Fisher Scientific, Inc.) and 1% penicillin-streptomycin (Gibco;
Thermo Fisher Scientific, Inc.). All cells were maintained in a
humidified atmosphere containing 5% CO₂ at 37°C.

Reagents and antibodies. DHCE was synthesized from
celastrol using the method previously described by
Klia et al (25). DHCE solution (2 mM) was dissolved in
dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA,
Darmstadt, Germany), stored at -20°C and diluted with
cell culture medium to obtain various concentrations. Antibodies against caspase-3 (cat. no. 9665, 1:1,000), cleaved
caspase-8 (cat. no. 9496, 1:1,000), caspase-9 (cat. no. 9508,
1:1,000), B-cell lymphoma 2 (Bcl-2)-associated protein
(Bax) (cat. no. 2772, 1:1,000), Bcl-2 (cat. no. 2872, 1:1,000),
Bcl-extra large (Bcl-xL) (cat. no. 2764, 1:1,000),
Akt (cat. no. 2920, 1:2,000), phosphorylated (p)-Akt
(cat. no. 4060, 1:2,000), p-p70S6K (cat. no. 9205, 1:1,000),
p70S6K (cat. no. 2708, 1:1,000), p-4E-BP1 (cat. no. 9456,
1:1,000), 4E-BP1 (cat. no. 9644, 1:1,000), p-mTOR (Ser2481)
(cat. no. 2974, 1:1,000), mTOR (cat. no. 2983, 1:1,000)
and β-actin (cat. no. 3700, 1:1,000) were purchased from
Cell Signaling Technology, Inc. (Danvers, MA, USA).
Cyclin D1 (cat. no. ab134175, 1:1,000), cyclin-dependent
kinase 4 (CDK4) (cat. no. ab108357, 1:1,000), CDK6
(cat. no. ab124821, 1:1,000), NF-κB inhibitor α (1xBo
(cat. no. ab32518, 1:1,000), p-1xBo (cat. no. ab92700, 1:1,000),
NF-κB-p65 (cat. no. ab32536, 1:50,000) and p-NF-κB-p65
(cat. no. ab76302, 1:10,000) were obtained from Abcam
(Cambridge, UK). The pan-caspase inhibitor Z-VAD-FMK
was purchased from Selleck Chemicals (Houston, TX, USA).
Cell Counting kit-8 (CCK-8) (cat. no. 111) was obtained from
Shanghai Yeasen Biotechnology Co., Ltd. (Shanghai, China)
and the BD Pharmingen™ Annexin V/propidium iodide (PI)
Apoptosis Detection kit was obtained from BD Biosciences
(Franklin Lakes, NJ, USA).

Cell viability assay. Jeko-1, Z138, Mino, Rec-1 and Granta519
cells were plated into 96-well plates at a density of 2x10⁵ cells/ml
and were treated with 0.2, 0.4, 0.6, 0.8 and 1.2 μM DHCE
for 24, 48 and 72 h. PBMCs were plated into 96-well plates at a
density of 3x10⁵ cells/ml and were treated with 1.6 μM DHCE
for 48 h. After incubation at 37°C and 5% CO₂, 10 μl CCK-8
solution was added to each well and the cells were incubated
for an additional 2 h at 37°C. Absorbance was then measured
at 450 nm using a microplate reader.

Cell apoptosis detection. Double-staining with the
BD Pharmingen™ Annexin V/PI Apoptosis Detection kit
was used to detect cell apoptosis. Following DHCE (0.4,
0.6 and 0.8 μM) and/or Z-VAD-FMK (50 μM) exposure
for 48 h, 1x10⁵ Jeko-1 and Z138 cells were resuspended in 95 μl
binding buffer and 5 μl fluorescein isothiocyanate-conjugated
Annexin V after centrifugation at 142 x g for 4°C for 5 min.
After incubation for 30 min at 4°C in the dark, 500 µl binding buffer and 20 µl PI solution were added to each cell suspension, and the BD FACSCanto II flow cytometer (BD Biosciences) was used for analysis by FlowJo 10 (FlowJo LLC, Ashland, OR, USA). Apoptotic cells were identified as Annexin V+/PI+ (early apoptosis) and Annexin V+/PI- (late apoptosis).

**Cell cycle analysis.** Following 0.4 and 0.8 µM DHCE exposure for 36 h, Jeko-1 and Z138 cells at a density of 2x10⁴ cells/ml were washed with cold PBS, and fixed in 70% ice-cold ethanol overnight at -20°C. The ethanol-fixed samples were washed with PBS, and incubated in 500 µl PI/RNase staining buffer (BD Biosciences) for 15 min at room temperature in the dark prior to flow cytometry. Results were analyzed by ModFit LT 3.2 (Verity Software House, Inc., Topsham, ME, USA). Clonogenic assay. Jeko-1 and Z138 cells (1x10⁴ cells/well) were mixed with RPMI-1640 media containing 10% FBS and 0.5% agar in each well of 6-well plates. After culturing for 36 h, Jeko-1 and Z138 cells at a density of 2x10⁵ cells/ml were washed with PBS, and incubated with 50 µM EdU (Guangzhou RiboBio Co., Ltd., Guangzhou, China) at 37°C for 48 h. Subsequently, all cells were treated with 0.5% Triton X-100 at room temperature for 10 min and washed three times with PBS. Thereafter, the cells were exposed to 100 µl 1X Apollo reaction cocktail at 37°C for 30 min and incubated with DAPI at room temperature to stain the cell nuclei for 5 min. A confocal laser-scanning microscope was used to detect stained cells.

**5-Ethynyl-2'-deoxyuridine (EdU) labeling and immunofluorescence.** Jeko-1 and Z138 cells were plated into a 6-well plate at a density of 4x10⁴ cells/well, and were incubated with or without 0.8 µM DHCE at 37°C for 48 h. Subsequently, all cells were incubated with 50 µM EdU (Guangzhou RiboBio Co., Ltd., Guangzhou, China) at 37°C for 1 h. After being fixed with 4% paraformaldehyde at room temperature for 30 min, the cells were treated with 0.5% Triton X-100 at room temperature for 10 min and washed three times with PBS. Thereafter, the cells were exposed to 100 µl 1X Apollo reaction cocktail at 37°C for 30 min and incubated with DAPI at room temperature to stain the tumor tissue sections for 24 h with DHCE (0.4, 0.6, 0.8 and 1.0 µM) and/or bortezomib (8, 12, 16 and 20 nM) (Sigma-Aldrich; Merck KGaA). Combination index (CI) values were calculated using the Chou-Talalay equation (27): CI values <1 indicated synergism; CI values equal to 1 indicated an additive effect; and CI values >1 indicated antagonism.

**Statistical analysis.** Data are expressed as the means ± standard deviation. Statistical analysis was conducted using an unpaired Student's t-test or one-way analysis of variance followed by least significant difference test for multiple comparisons. All statistical analyses were performed using SPSS version 20.0 statistical analysis software (IBM Corp., Armonk, NY, USA). P≤0.05 was considered to indicate a statistically significant difference.

**Results**

**DHEC inhibits MCL cell growth and proliferation.** As shown in Fig. 1A, DHEC is a synthesized dihydro-analog compound with a molecular weight of 452.6. In the present study, five
MCL cell lines (Jeko-1, Z138, Granta519, Mino and Rec-1) were treated with various doses of DHCE. After 48 h of DHCE exposure, cell viability was measured using a CCK-8 assay. MCL cell viability was decreased in a dose-dependent manner (Fig. 1B), and the 48 h half maximal inhibitory concentration values of DHCE in Jeko-1, Z138, Mino, Rec-1 and Granta519 cells were 0.65±0.10, 0.45±0.04, 0.42±0.01, 0.35±0.03 and 0.91±0.08 µM, respectively. Jeko-1 and Z138 cells were selected for subsequent analyses, as they have previously been used in numerous studies regarding MCL (28,29). Furthermore, a time-course study of DHCE further demonstrated that cell viability was inhibited in a time-dependent manner.
manner (Fig. 1C). Conversely, at concentrations as high as 1.6 µM, DHCE conferred minimal cytotoxic effects on normal PBMCs obtained from three healthy volunteers (Fig. 1D). To investigate the inhibitory effects of DHCE on tumorigenic potential, anchorage-independent colony formation in soft agar was compared between the control and treatment groups. DHCE treatment reduced the ability of Jeko-1 and Z138 cells to form tumorspheres in a dose-dependent manner, and colony formation was almost completely inhibited among Z138 cells treated with 0.8 µM DHCE (Fig. 1E). To further explore the effects of DHCE on cell proliferation, the integration of EdU was measured, in order to detect the levels of DNA synthesis; cell nuclei were stained with DAPI. The results demonstrated that DHCE suppressed DNA synthesis in MCL cells, thus indicating that DHCE inhibited proliferation of MCL cells (Fig. 1F). These findings suggested that DHCE may decrease cell viability and inhibit cell proliferation in a dose- and time-dependent manner; however, DHCE is not cytotoxic to normal cells.

**DHCE promotes cell cycle arrest in MCL cells.** The cyclin D1-CDK4 and cyclin D1-CDK6 complexes are critical for the G1/S checkpoint, and regulate the progression of cells from G1 phase to S phase (30). To evaluate the effects of DHCE on cell cycle progression, Jeko-1 and Z138 cells were treated with DHCE and analyzed by flow cytometry. The results demonstrated that DHCE inhibited proliferation of MCL cells (Fig. 1F). These findings suggested that DHCE may decrease cell viability and inhibit cell proliferation in a dose- and time-dependent manner; however, DHCE is not cytotoxic to normal cells.

**DHCE induces apoptosis of MCL cells.** Evasion of apoptosis has a key role in tumorigenesis and chemotherapeutic resistance (31). To investigate whether apoptosis is associated with the mechanism underlying the cytotoxic effects of DHCE, Jeko-1 and Z138 cells were incubated with various concentrations of DHCE for 48 h. DHCE markedly increased the percentage of apoptotic cells in a dose-dependent manner, compared with in the control group (Fig. 3A). Furthermore, Jeko-1 and Z138 cells were simultaneously treated with DHCE and a pan-caspase inhibitor, Z-VAD-FMK. The results demonstrated that Z-VAD-FMK induced a significant reduction in DHCE-induced cell apoptosis (Fig. 3B; data of Z138 cells not shown), thus indicating that DHCE-mediated apoptosis is dependent upon caspase activity. These findings demonstrated that DHCE may induce MCL cell apoptosis in a dose-dependent manner.

**DHCE induces DNA strand breaks due to apoptosis.** A series of morphological alterations are triggered when apoptosis is activated, including cell shrinkage, aberrant chromatin compaction, DNA hydrolysis, nuclear fragmentation and the formation of apoptotic bodies (32). To directly confirm that DHCE promoted the apoptosis of MCL cells, a confocal laser-scanning microscope was used to detect the binding of TUNEL reagent with DNA fragments. Compared with in the control group, MCL cells treated with DHCE for 48 h exhibited chromatin fragmentation (Fig. 3C), which is a typical morphological characteristic of apoptotic cells.
These cytological observations further confirmed that DHCE promotes the apoptosis of MCL cells.

**Figure 3.** DHCE induces apoptosis of mantle cell lymphoma cells. (A) Cells were treated with DHCE for 48 h and analyzed by FACS using Annexin V/PI staining. Statistical analysis of apoptosis is presented in the right panel. (B) Cells were incubated with or without the pan-caspase inhibitor Z-VAD-FMK, and were then treated with 0.8 µM DHCE for 48 h, stained with Annexin V/PI and analyzed by FACS. Statistical analysis of apoptosis is presented in the right panel. (C) Representative fluorescent images (original magnification, x50) detected increased numbers of apoptotic cells, as evaluated by TUNEL staining (green), following treatment with 0.8 µM DHCE for 48 h. DAPI was used as a nuclear stain (blue). The overall number of TUNEL-positive cells was determined and analyzed in the right panel. (D) Expression levels of apoptosis-associated proteins were analyzed using western blot analysis, with β-actin used as an internal control. Data are expressed as the means ± standard deviation (n=3). *P<0.05, **P<0.01, ***P<0.001 compared with the 0 µM group, or as indicated.

DHCE induces caspase-dependent apoptosis through the extrinsic and intrinsic pathways. It is widely known that
apoptosis signaling pathways consist of extrinsic and intrinsic pathways. Upon receiving specific signals instructing the cells to undergo apoptosis, caspase proteases lead to the cleaving of cellular components including structural proteins in the cytoskeleton and nuclear proteins, such as DNA repair enzymes, through extrinsic and intrinsic pathways (31). DHCE markedly activated caspase-8 and caspase-3 (Fig. 3D), which are associated with the extrinsic pathway of apoptosis. In addition, DHCE suppressed the expression of the ant-apoptotic proteins Bcl-2 and Bcl-xL, and upregulated the expression of Bax, which is a proapoptotic protein of the intrinsic pathway (Fig. 3D) (33). Increased procaspase-9 substrate cleavage was also detected (Fig. 3D). These findings suggested that DHCE may activate the extrinsic and intrinsic pathways of apoptosis in a dose-dependent manner.

**DHCE suppresses mTORC1/p70S6K/4E-BP1.** mTORC1 phosphorylates p70S6K and 4E-BP1, which are the two best-characterized downstream targets of mTORC1, thus regulating protein translation and contributing to cell growth and proliferation. To address the potential involvement of mTORC1 in DHCE-mediated inhibition of MCL cell proliferation, the present study measured the protein expression levels of p70S6K and 4E-BP1. Western blot analysis of Jeko-1 and Z138 cells demonstrated that phosphorylation of p70S6K and 4E-BP1 was inhibited by DHCE in a dose-dependent manner (Fig. 4A). Although DHCE treatment decreased the total protein expression of 4E-BP1 after 24 h, phosphorylation of 4E-BP1 was markedly inhibited compared with the control. These results indicated that DHCE-mediated inhibition of cell proliferation and growth may result from the suppression of mTORC1/p70S6K/4E-BP1 activity (Fig. 4B).

**DHCE blocks mTORC2/Akt/NF-κB activity signaling.** In contrast to mTORC1, mTORC2 modulates cell survival and apoptosis. Unlike rapamycin, a highly potent and selective inhibitor of mTORC1, which has little or no apoptotic effects on MCL cells (34), DHCE strongly induced apoptosis of Jeko-1 and Z138 cells (Fig. 3). Previous studies demonstrated that Akt regulated the activation of NF-κB, and that NF-κB can be stimulated downstream of mTORC2 by either Akt-dependent or Akt-independent mechanisms (35-38). The present western blot analysis results demonstrated that treatment of MCL cells with DHCE downregulated the protein expression levels of NF-κB target genes, including Bcl-2, Bcl-xL and cyclin D1. Therefore, it was hypothesized that DHCE may
 Induce apoptosis of MCL cells by suppressing mTORC2/Akt/NF-κB signaling. Treatment of cells with DHCE resulted in a marked, dose-dependent inhibition of Akt (Ser473) and mTOR (Ser2481) phosphorylation in Jeko-1 and Z138 cells compared with the control group (Fig. 4C). DHCE treatment exerted only a minimal effect on total mTOR and total Akt protein expression. Subsequently, the effects of DHCE on NF-κB activity were assessed and demonstrated that DHCE treatment resulted in decreased IkBa and NF-κB-p65 phosphorylation. These findings suggested that DHCE may block the activity of mTORC2/Akt/NF-κB, thus leading to apoptosis and inhibition of cell survival (Fig. 4B).

**DHCE inhibits tumor growth in a xenograft mouse model.**

The present study further examined the therapeutic efficacy of DHCE using a xenograft mouse model. Nude mice bearing subcutaneous Jeko-1 cell xenograft tumors were administered daily intraperitoneal injections of either DHCE (3 mg/kg) or a vehicle control. The diameter and volume of the largest tumor in these mice was 1.98 cm and 3.20 cm³, respectively. DHCE treatment markedly decreased tumor size (Fig. 5A) and significantly decreased tumor volume (Fig. 5B); however, body weight was not significantly altered between the DHCE-treated and vehicle-treated mice (Fig. 5C). The results of H&E staining demonstrated that necrosis in the tumor samples of the DHCE-treated group was increased compared with the vehicle control group. TUNEL staining revealed that DHCE treatment increased apoptosis compared with the vehicle control group (Fig. 5D). DHCE treatment was well tolerated; no symptoms of poor health or abnormal behaviors were observed in DHCE-treated or vehicle-treated mice, and microscopic examination of individual organs revealed no evidence of tissue damage in either treatment group (data not shown). Consistent with the in vitro observations, these in vivo findings demonstrated that DHCE may inhibit MCL tumor growth in a xenograft model without exerting lethal toxicity.

**DHCE acts synergistically with bortezomib in MCL cells.**

Combination chemotherapy is a rational strategy for the treatment of MCL (4). Combination treatment with DHCE and bortezomib inhibited growth in both cell lines to a greater degree than treatment with DHCE or bortezomib alone. In the present study, CI values were <1.0, indicating synergism of DHCE and bortezomib (Fig. 6). Combined treatment of MCL cells with DHCE and bortezomib exhibited clear synergistic effects on the inhibition of cell proliferation.

**Discussion**

Despite recent developments resulting in the generation of novel treatment regimens for MCL, the disease remains incurable, with many patients experiencing short periods of remission followed by continuous relapse. Novel drugs are required to further improve the outcome of patients with MCL. Numerous reports have confirmed that the triterpenoid celastrol is an effective antitumor analog in leukemia, breast cancer, gastric cancer, head and neck cancer, and multiple myeloma (22-24). However, little is currently known regarding the use of this compound in lymphoma, and to the best of our knowledge, the present study is the first to directly assess the use of a triterpenoid in MCL. DHCE is a novel triterpene, and the present study explored the effects and relevant mechanisms of DHCE in MCL cells.

Cell cycle dysregulation and evasion of apoptosis, both of which are hallmarks of tumor cells, contribute to tumorigenesis and chemical resistance (39). In general, when confronted with...
stress or damage, cells activate DNA damage checkpoints and initiate DNA repair; however, with persistent cellular impairments, DNA damage cannot be appropriately repaired and the DNA damage checkpoint pathway is activated to eliminate potentially harmful DNA-damaged cells via apoptosis (40). Targeting the apoptosis pathways is a promising opportunity to eradicate cancer (31). Cyclin D1, along with CDK4 and CDK6, regulates G1/S progression through phosphorylation of retinoblastoma protein (39). Treatment of MCL cells with DHCE resulted in a downregulation of cyclin D1, CDK4 and CDK6 expression, which then led to G2/M phase cell cycle arrest. Fluorescence-activated cell sorting analysis and TUNEL/DAPI double staining revealed that DHCE induced apoptosis of MCL cells in a dose-dependent manner, which was suppressed by the pan-caspase inhibitor Z-VAD-FMK. The ability of DHCE to induce apoptosis was associated with the activity of apoptotic proteins. Proteins of the Bcl-2 family are key regulators of the intrinsic apoptotic pathway, including Bcl-2, Bcl-xL and Bax, which ultimately activate caspase-9 at the apoptosome (41). Caspase-8 is a key initiator caspase that can directly activate caspase-3, thus promoting apoptosis via the extrinsic pathway (31). DHCE treatment resulted in downregulation of caspase-3, caspase-8 and caspase-9. Furthermore, DHCE treatment decreased the expression of the proapoptotic mitochondrial protein Bax. These findings suggested that DHCE treatment may induce the caspase-dependent apoptosis of MCL cells via extrinsic and intrinsic apoptotic pathways.

The mTOR pathway is considered a promising target for cancer therapeutics (42,43). mTORC1 activity affects cell growth and metabolism by phosphorylating p70S6K and 4E-BP1, which regulate protein synthesis, as well as lipid, nucleotide and glucose metabolism. Upon phosphorylation, p70S6K becomes activated, which is critical for lipid and ribosome biogenesis pathways and protein translation. The phosphorylation of 4E-BP1 causes its dissociation from the translation initiation factor eukaryotic translation initiation factor 4E, thus triggering 5'cap-dependent mRNA translation (44). mTORC2 controls apoptosis by autophosphorylating mTOR on Ser2481 with Rictor, and by phosphorylating Akt on Ser473 (7). Rapamycin, which is a well-known mTORC1 inhibitor, and analogs of rapamycin, incompletely inhibit mTORC1 and only inhibit mTORC2 when administered at high doses for a prolonged duration (34,44), due to the presence of a negative feedback loop between mTORC1 and the insulin/PI3K signaling pathway. mTORC1 phosphorylates growth factor receptor bound protein 10 to inhibit insulin/insulin-like growth factor 1 receptor signaling, which is an upstream activator of Akt and mTORC2. Therefore, inhibition of mTORC1 alone removes the negative feedback on insulin/PI3K/Akt signaling, allowing Akt to become activated, which ultimately promotes cell survival and prevents apoptosis (45). Other similar feedback mechanisms also exist, which limit the effectiveness of mTORC1 inhibitors. Treatment of established cell lines or primary MCL cultures with rapamycin induces little or no apoptotic response (34). Inhibition of mTORC1 alone has negligible effects on apoptosis in several cell lines; however, suppressing both mTORC1 and mTORC2 presents a more effective strategy. In the present study, it was demonstrated that treatment of MCL cells with DHCE reduced p70S6K and 4E-BP1 phosphorylation, indicating that DHCE suppressed mTORC1 activity. Therefore, it may be concluded that DHCE inhibits the growth and proliferation of MCL cells through suppression of the mTORC1/p70S6K/4E-BP1 pathway.

Although the activity of mTORC1 can be assessed by determining the phosphorylation status of its downstream substrates, a specific downstream marker of mTORC2 activity has not been identified to date. Previous studies have demonstrated...
that knockdown of the mTORC2 protein Rictor, but not the mTORC1 protein Raptor, significantly inhibits activity of Akt as well as that of NF-κB (46,47), which controls cell survival and apoptosis (48,49). Once phosphorylated by mTORC2, Akt regulates transcriptional activity of NF-κB by inducing phosphorylation and subsequent degradation of IκB (36), or by phosphorylating IκB kinase, which increases the activity of NF-κB and stimulates the transcription of prosurvival genes (42). In addition, mTORC2 directly promotes NF-κB activation through the serum/glucocorticoid-regulated kinase 1-dependent pathway or via the phosphorylation of protein kinase C (35,37,38). In the present study, it was demonstrated that phosphorylation of mTOR (Ser2481) and Akt (Ser473) were significantly decreased in MCL cells following treatment with DHCE, thus indicating that DHCE inhibited mTORC2. Consistent with these findings, a reduction in the phosphorylation of IκBα and NF-κB-p65 was observed, thus indicating the reduction of NF-κB activity. Due to the suppression of NF-κB activity, the expression levels of NF-κB targets, including Bcl-2, Bcl-xL and cyclin D1, were also decreased. Therefore, DHCE may exhibit a potent apoptotic effect on MCL cells due to the suppression of mTORC2/Akt/NF-κB activity. These findings are in agreement with previous studies (35,37,38). However, a recent report indicated that mTORC2 activity suppresses NF-κB signaling (50). Further studies are required to determine how mTORC1 and mTORC2 regulate NF-κB activity.

In the present study, DHCE was able to suppress tumor growth in vivo without causing toxicity by inducing the apoptosis of MCL cells. Intraperitoneal administration of 3 mg/kg DHCE for 19 days resulted in a significant inhibition of tumor growth, with no clear indications of toxicity. Consistent with the in vitro results, immunohistochemical analysis of the tumor samples confirmed that DHCE administration induced apoptosis.

Combined treatment of MCL cells with DHCE and bortezomib, a proteasome inhibitor, enhanced the inhibition of cell proliferation that was achieved with DHCE or bortezomib alone. To further evaluate the synergy between the two drugs, the CI values were calculated: the results demonstrated that values were <1.0, thus indicating that DHCE and bortezomib acted synergistically to induce cytotoxicity in MCL cells. Bortezomib is approved for use by the Food and Drug Administration of United States of America and is currently used in MCL treatment regimens. Combination therapies are often used as a strategy to minimize cytotoxicity and resistance (4). The present results indicated that combined therapy with DHCE and bortezomib may be a promising strategy to overcome cytotoxicity and resistance in patients with MCL. However, further validation and exploration is required to fully determine the cooperative mechanism and synergism between these drugs.

In conclusion, DHCE exhibited potent antitumor activity in MCL cell lines and in an MCL xenograft model, at doses that have little effect on normal cells and are well tolerated in mice. The results demonstrated that DHCE suppressed cell growth and proliferation by inhibiting mTORC1-mediated phosphorylation of p70S6K and 4E-BP1. Simultaneously, DHCE induced apoptosis and inhibited cell survival by suppressing mTORC2-mediated phosphorylation of Akt and NF-κB activity. Furthermore, combined treatment with DHCE and bortezomib resulted in synergistic cytotoxic effects on MCL cells. The present study therefore supported the important role of the mTOR pathway in the tumorigenesis of MCL, thus suggesting the necessity of dually inhibiting mTORC1/p70S6K/4E-BP1 and mTORC2/Akt/NF-κB activity in MCL therapy. With further investigation into the associated molecular mechanisms and clinical implications of DHCE administration, DHCE has the potential to serve as a novel therapeutic regimen to improve the outcomes of patients with MCL.

Acknowledgements

The authors would like to thank Dr. Xue Han of Tianjin Medical University Cancer Hospital (Tianjin, China) for providing the human MCL cell lines.

Funding

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81570190, 81529001, 81670194 and 81602515).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

JS, WZ, YX, and BL designed the research; JS, WZ, YX, and BL organized, analyzed, and interpreted the data; YX, BL, WB, LG, YoZ, XL, JH, ZX, SC, DY, BX, YW, HW and XW performed the experiments; JS, WZ, YX and BL drafted the manuscript; JH, HW and YiZ contributed to clinical sample collection. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Informed consent was obtained from each healthy donor. The present study was approved by the institutional review board of Shanghai Tenth People's Hospital (Shanghai, China). All animal studies were approved by the institutional review board of the Shanghai Tenth People's Hospital (ID: SYXK 2011-0111).

Patient consent for publication

All volunteers consent to the publication.

Competing interests

The authors declare that they have no competing interests.

References


